GenFleet: building a fleet of first-in-class cancer and immune therapies

GenFleet was founded in 2017 to pursue oncology and immunology targets backed by strong scientific rationale but lacking clinical validation, bucking the trend of Chinese companies sticking to “safe” targets such as PD-1. It aims to be first-in-class worldwide, although its first program won’t be.

“The idea since inception has always been that we would not like to be a ‘me too’ or even a ‘me better’ kind of company,” co-founder and Chairman Qiang Lu told BioCentury. ...